In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of N/A.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | N/A | |
2022 | N/A | |
2021 | N/A | |
2020 | N/A | |
2019 | N/A | |
2018 | N/A | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | |
2013 | N/A | |
2012 | N/A | |
2011 | N/A | |
2010 | N/A | |
2009 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | $27.11 B | N/A | ๐บ๐ธ USA |
Merck MRK | $60.11 B | N/A | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.00 B | N/A | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $37.84 B | N/A | ๐ฌ๐ง UK |
Novavax NVAX | $0.69 B | N/A | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $0.33 B | N/A | ๐บ๐ธ USA |